Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.79 |
| ▸ | RAB9A | P51151 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001406 | 0.97 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2002051 | 0.88 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL218275 | 0.88 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL29366631 | 0.88 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL30409810 | 0.86 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL20547489 | 0.86 | YTHDC1 (0.61) | NPC1RAB9ASMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL2389569 | 0.86 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL30410344 | 0.85 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2003798 | 0.85 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL20547428 | 0.84 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960397-B2 | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions | INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2011-06-14 | — | — | US | claimed |
| EP-2245031-B1 | 6,9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE AS COSMETICS AND COSMETIC COMPOSITIONS | INST OF EX BOTANY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2014-02-26 | — | — | EP | disclosed |
| US-8575182-B2 | 6, 9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions | Institute of Experimental Botany, Academy of Sciences of the Czeck Republic (CZ) | 2013-11-05 | — | — | US | disclosed |
| US-20110230503-A1 | 6, 9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | SZUCOVA LUCIE | 2011-09-22 | — | — | US | disclosed |
| US-7960397-B2 | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions | INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2011-06-14 | — | — | US | disclosed |
| EP-2245031-A2 | 6,9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE AS COSMETICS AND COSMETIC COMPOSITIONS | Institute of Experimental Botany, Academy of Sciences of the Czech Republic (CZ) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009086457-A2 | 6,9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE AS COSMETICS AND COSMETIC COMPOSITIONS | INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2009-07-09 | — | — | WO | disclosed |
| US-20090170879-A1 | 6,9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | SZUCOVA LUCIE | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170879-A1 | 6,9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | P2RY6, UMPS, PNP | NPC1 3155/4885RAB9A 852/4885SMN1; SMN2 3639/4885 |
| US-20110230503-A1 | 6, 9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | P2RY6, UMPS, PNP | NPC1 3155/4885RAB9A 852/4885SMN1; SMN2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.